Centre Hospitalier Regional et Universitaire de Lille-ko ikertzaileekin lankidetzan egindako argitalpenak (28)

2022

  1. Correction to: Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis (Advances in Therapy, (2022), 39, 5, (1976-1992), 10.1007/s12325-022-02083-8)

    Advances in Therapy

  2. Corrigendum to 'Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up': [Ann Oncol 2021; 32(3): 309-322

    Annals of oncology : official journal of the European Society for Medical Oncology

  3. Corrigendum: “Corrigendum to ‘Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up’”: (Annals of Oncology (2022) 33(1) (117), (S0923753421044999), (10.1016/j.annonc.2021.10.001))

    Annals of Oncology

  4. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

    Blood, Vol. 140, Núm. 11, pp. 1229-1253

2021

  1. Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up

    HemaSphere, Vol. 5, Núm. 2

2020

  1. First-in-Human Phase I Study of ABBV-838, an Antibody–Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma

    Clinical Cancer Research, Vol. 26, Núm. 10, pp. 2308-2317

2019

  1. Insights on Multiple Myeloma Treatment Strategies

    HemaSphere, Vol. 3, Núm. 1

  2. Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial

    The Lancet Haematology, Vol. 6, Núm. 9, pp. e448-e458

2017

  1. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Annals of Oncology, Vol. 28, pp. iv52-iv61

  2. Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the European myeloma network

    Leukemia, Vol. 2017

2015

  1. American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma

    Biology of Blood and Marrow Transplantation, Vol. 21, Núm. 12, pp. 2039-2051

2014

  1. Combination of International Scoring System 3, highlactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related death

    Journal of Clinical Oncology, Vol. 32, Núm. 20, pp. 2173-2180

  2. European perspective on multiple myeloma treatment strategies in 2014

    Oncologist, Vol. 19, Núm. 8, pp. 829-844

2013

  1. Plasma cell leukemia: Consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group

    Leukemia, Vol. 27, Núm. 4, pp. 780-791

2012

  1. European perspective on multiple myeloma treatment strategies: Update following recent congresses

    Oncologist, Vol. 17, Núm. 5, pp. 592-606

  2. IMWG consensus on maintenance therapy in multiple myeloma

    Blood, Vol. 119, Núm. 13, pp. 3003-3015

2011

  1. Multiple myeloma treatment strategies with novel agents in 2011: A European perspective

    Oncologist, Vol. 16, Núm. 4, pp. 388-403

2010

  1. Current multiple myeloma treatment strategies with novel agents: A European perspective

    Oncologist, Vol. 15, Núm. 1, pp. 6-25

  2. Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues

    The Lancet Oncology, Vol. 11, Núm. 11, pp. 1086-1095

2009

  1. Frontline Treatment in Elderly Patients With Multiple Myeloma

    Seminars in Hematology, Vol. 46, Núm. 2, pp. 133-142